Literature DB >> 6873147

Pharmacokinetics of hydrochlorothiazide in relation to renal function.

C Niemeyer, G Hasenfuss, U Wais, H Knauf, M Schäfer-Korting, E Mutschler.   

Abstract

The pharmacokinetics of hydrochlorothiazide (HCT) was investigated in 23 subjects with normal renal function or widely varying degrees of renal failure. The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min. The cumulative urinary excretion and the renal HCT clearance were correspondingly reduced in patients with impaired kidney function. In normal subjects HCT was mainly excreted by tubular secretion, but as renal HCT clearance in patients with renal impairment did not differ significantly from endogenous creatinine clearance, it was concluded that the secretory mechanism is most markedly impaired. In patients with an endogenous creatinine clearance of 30 to 90 ml/min, the dosage of HCT should be reduced to 1/2 and in patients with a endogenous creatinine clearance below 30 ml/min to 1/4 of the normal daily dose to avoid dose dependant side-effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873147     DOI: 10.1007/bf00542218

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  C14-labeled hydrochlorothiazide in human beings.

Authors:  K V ANDERSON; H R BRETTELL; J K AIKAWA
Journal:  Arch Intern Med       Date:  1961-05

2.  Alteration of protein-binding during storage of human plasma preparations.

Authors:  G Baur; H Kurz; H Trunk
Journal:  Anaesthesist       Date:  1977-03       Impact factor: 1.041

3.  [Fluorometric determination of hydrochlorothiazide in body fluids by direct measurement of thin-layer chromatographic plates (author's transl)].

Authors:  M Schäfer; H E Geissler; E Mutschler
Journal:  J Chromatogr       Date:  1977-11-01

4.  Bioavailability of two hydrochlorothiazide preparations.

Authors:  B Beermann; M Groschinsky-Grind; B Lindstrom
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

5.  Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

6.  Absorption, metabolism, and excretion of hydrochlorothiazide.

Authors:  B Beermann; M Groschinsky-Grind; A Rosén
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

7.  Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug.

Authors:  B Beermann; M Groschinsky-grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

8.  Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease.

Authors:  B L Mirkin; T P Green; R F O'Dea
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

9.  Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

10.  Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.

Authors:  L Jordö; G Johnsson; P Lundborg; B A Persson; C G Regärdh; O Rönn
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

View more
  18 in total

Review 1.  Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.

Authors:  Julio D Duarte; Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-06

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 4.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

5.  Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.

Authors:  Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Sreedevi Boggarapu; Gangadhar Sunkara
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

6.  Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers.

Authors:  S A Riley; M Kim; F Sutcliffe; M Kapas; M Rowland; L A Turnberg
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

7.  Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.

Authors:  R A Upton; R L Williams; E T Lin; W L Gee; C D Blume; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

8.  The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.

Authors:  K Weisser; J Schloos; S Jakob; W Mühlberg; D Platt; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 9.  Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.

Authors:  Caroline Fenton; Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.

Authors:  K Sabanathan; C M Castleden; H K Adam; J Ryan; T J Fitzsimons
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.